Numerous ADC Therapeutics Insiders Sold Stock: Not A Positive Omen
Numerous ADC Therapeutics Insiders Sold Stock: Not A Positive Omen
ADC Therapeutics SA (NYSE:ADCT) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.
在過去的一年中，ADC Therapeutics SA（紐交所ADCT），多名內部人士出售了其股份，股東可能有理由擔心。分析內部交易時，通常更有價值的是了解內部人員正在購買還是出售股票，後者發送的信息是模棱兩可的。但是，如果有數名內部人士在特定時間段內出售股票，股東應該深入研究。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
雖然我們永遠不會建議投資者僅基於公司董事已經做出的決策而做出決策，但同時我們認爲完全忽略內部交易是愚蠢的。
The Last 12 Months Of Insider Transactions At ADC Therapeutics
ADC Therapeutics的過去12個月內的內部交易情況
Over the last year, we can see that the biggest insider sale was by the CEO & Director, Ameet Mallik, for US$133k worth of shares, at about US$4.48 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$3.68). So it may not shed much light on insider confidence at current levels.
在過去的一年中，我們可以看到，首席執行官和董事Ameet Mallik的最大內部銷售額爲13.3萬美元，每股約4.48美元的股份。我們通常不喜歡看到內部人員出售股票，但是銷售價格越低，我們就越關注。好消息是，這次拋售是在最新價格（3.68美元）以上進行的。因此，在現有水平上，它可能不會爲內部信心提供太多信息。
Insiders in ADC Therapeutics didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
ADC Therapeutics的內部人士在過去一年中沒有購買任何股份。您可以在下面看到（按公司和個人）過去12個月內內部交易的視覺描繪。如果單擊圖表，您可以查看全部個人交易，包括股票價格、個人和日期！
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
對於那些喜歡發現潛力股票的人，可以免費查看最新內部交易股票的小盤公司名單，這可能正是您要找的機會。
Insiders At ADC Therapeutics Have Sold Stock Recently
ADC Therapeutics的內部人士最近拋售了股票
The last quarter saw substantial insider selling of ADC Therapeutics shares. Specifically, insiders ditched US$267k worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.
最後一個季度ADC Therapeutics的內部人員大量出售了其股份。具體而言，在這段時間內，內部人員拋售了267000美元的股票，而我們沒有記錄任何購買行爲。這可能表明，一些內部人員認爲這些股票並不便宜。
Insider Ownership Of ADC Therapeutics
ADC Therapeutics的內部所有權
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. ADC Therapeutics insiders own about US$14m worth of shares. That equates to 4.6% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
許多投資者喜歡檢查公司現有的內部所有權比例。高的內部所有權往往使公司領導層更加關注股東利益。ADC Therapeutics的內部人員持有價值約1400萬美元的股份。這相當於公司的4.6%。這種內部所有權水平不錯，但稍短於特別顯眼。股東和管理層利益的合理程度可能比較高。
What Might The Insider Transactions At ADC Therapeutics Tell Us?
ADC Therapeutics內部交易可能告訴我們什麼？
Insiders haven't bought ADC Therapeutics stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. We'd practice some caution before buying! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For instance, we've identified 5 warning signs for ADC Therapeutics (1 is significant) you should be aware of.
過去三個月內，內部人士沒有購買ADC Therapeutics的股票，但是有一些出售。回顧過去的12個月，我們的數據沒有顯示任何內部人員購買的情況。內部所有權並不特別高，因此這使我們對公司保持謹慎態度。在購買之前，我們要謹慎行事！因此，了解內部人員是否正在購買或出售股票很有幫助，同時了解特定公司面臨的風險也很有幫助。例如，我們已確定ADC Therapeutics存在5個警告信號（其中1個是重要的），您應該注意。
But note: ADC Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意：ADC Therapeutics可能不是最好的股票。因此，請查看這個免費列表，其中包含具有高ROE和低債務的有趣公司。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。